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Abstract
Mangiferin has been shown to have the effect of improving dyslipidemia. Plasma free fatty acids (FFA) are closely associated
with blood lipid metabolism as well as many diseases including metabolic syndrome. This study is to investigate whether
mangiferin has effects on FFA metabolism in hyperlipidemic rats. Wistar rats were fed a high-fat diet and administered
mangiferin simultaneously for 6 weeks. Mangiferin (50, 100, 150 mg/kg BW) decreased dose-dependently FFA and
triglycerides (TG) levels in plasma, and their accumulations in liver, but increased the b-hydroxybutyrate levels in both
plasma and liver of hyperlipidemic rats. HepG2 cells were treated with oleic acid (OA, 0.2 mmol/L) to simulate the condition
of high level of plasma FFA in vitro, and were treated with different concentrations of mangiferin simultaneously for 24 h.
We found that mangiferin significantly increased FFA uptake, significantly decreased intracellular FFA and TG accumulations
in HepG2 cells. Mangiferin significantly increased AMP-activated protein kinase (AMPK) phosphorylation and its downstream
proteins involved in fatty acid translocase (CD36) and carnitine palmitoyltransferase 1 (CPT1), but significantly decreased
acyl-CoA: diacylgycerol acyltransferase 2 (DGAT2) expression and acetyl-CoA carboxylase (ACC) activity by increasing its
phosphorylation level in both in vivo and in vitro studies. Furthermore, these effects were reversed by Compound C, an
AMPK inhibitor in HepG2 cells. For upstream of AMPK, mangiferin increased AMP/ATP ratio, but had no effect on LKB1
phosphorylation. In conclusion, mangiferin decreased plasma FFA levels through promoting FFA uptake and oxidation,
inhibiting FFA and TG accumulations by regulating the key enzymes expression in liver through AMPK pathway. Therefore,
mangiferin is a possible beneficial natural compound for metabolic syndrome by improving FFA metabolism.
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Introduction
A large body of evidence suggests that elevated plasma free fatty
acids (FFA) are a risk factor for metabolic syndrome, including
insulin resistance, atherogenic dyslipidemia and type 2 diabetes
[1,2]. Elevated FFA can inhibit the anti-lipolytic action of insulin,
interfere with insulin signaling, and inhibit insulin-stimulated
glucose uptake and glycogen synthesis [3,4]. Therefore, pharma-
cological agents that could effectively lower plasma FFA are likely
to have a significant effect on improving metabolic syndrome [5].
The liver is an important site of FFA removal from the blood
[6]. At rest, about 80% of plasma FFA is mainly transported to the
liver where they are either oxidized to generate energy in the form
of ATP, or re-esterified for storage as triglycerides (TG) [7,8]. Not
surprisingly, increased plasma FFA levels may result in intracel-
lular accumulation of lipid metabolites in the liver, leading to fatty
liver, liver insulin resistance and type 2 diabetes. Therefore, one
potential strategy for improving metabolic syndrome is not only to
reduce the level of plasma FFA, but also to promote FFA uptake
and oxidation instead of accumulation of intracellular TG in the
liver.
Mangiferin is a xanthone glucoside and exists in many kinds of
food and folk medicines such as mangoes and Anemarrhena
asphodeloides rhizomes. Mangiferin has many beneficial biological
activities, including anti-inflammatory, anti-oxidant and anti-
diabetic effects [9,10]. Recent studies showed that mangiferin
significantly reduced the level of plasma TG in diabetic animals
[11,12]. Plasma TG must first be hydrolyzed into FFA and
glycerol, and then is taken up and utilized by tissues in the form of
FFA [13,14]. Therefore, plasma TG metabolism is associated
closely with plasma FFA. However, there are no reports on
whether mangiferin can affect FFA levels or FFA metabolism in
liver. Therefore, the aim of our study was to investigate the effects
of mangiferin on plasma FFA levels, FFA metabolism and its
possible mechanisms. Using both in vivo and in vitro models, we
found mangiferin was able to decrease the levels of plasma FFA,
promote FFA catabolism, and inhibit the synthesis of FFA and TG
in liver through AMPK signaling pathway.
Results
Mangferin had no toxic effect in rats and HepG2 cells
Rats were fed with different concentrations of mangiferin (0,
100, 200, 400 mg/kg BW) for 30 days. There were no significant
effects on body weight, blood cell counting, hemoglobin, urea
nitrogen, creatinine, blood glucose, total cholesterol, triglycerides,
aspartate transaminase and alanine transaminase activity (Table
S1). This indicated that mangiferin was nontoxic up to the dose of
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At the same time, after 24 h mangiferin treatment, cytotoxicity
was observed when the concentration of mangiferin reached
400 mmol/L (data not shown). Therefore, mangiferin concentra-
tion was safe within 12.5–100 mmol/L/L in the present study.
Mangiferin decreased plasma FFA and TG levels, and
inhibited liver FFA and TG accumulations in
hyperlipidemic rat
At the end of 6 weeks, the rats in hyperlipidemia group had
higher levels of TC (P,0.05), TG (P,0.01) and FFA (P,0.01) in
both plasma and liver tissue compared with rats in normal control
(Table 1), indicating that the high-fat diet induced successfully
hyperlipidemic rats model with triglycerides, FFA and cholesterol
accumulations in the liver. Fenofibrate (a positive drug) and all
doses of mangiferin supplementation significantly decreased
plasma FFA level (P,0.05), and fenofibrate and mangiferin at
100 or 150 mg/kg BW significantly decreased plasma TG level
(P,0.01), and liver FFA (P,0.01) and TG (P,0.01) levels in
hyperlipidemic rats. In addition, fenofibrate and high dose of
mangiferin may decrease the weights of abdominal and epididy-
mal fat pads in hyperlipidemic rats (Table 1). Mangiferin had a
tendency of lowering TC in all the doses, but did not reach the
statistical significance.
Mangiferin regulated the key enzymes of FFA
metabolism and TG synthesis in liver of hyperlipidemic
rat
AMPK is a key mediator in the control of intracellular lipid
metabolism, including the uptake, synthesis and oxidation of fatty
acid in liver [20]. Mangiferin significantly activated hepatic
AMPKa subunit (P,0.05, Figure 1A) by phosphorylating
AMPKa at the Thr-172 residue in hyperlipidemic rats. The
downstream proteins of AMPK including CD36, CPT1, ACC
and DGAT2 were also affected by mangiferin treatment. The
expression of CD36 protein, which is involved in regulating FFA
uptake [21], was increased significantly by mangiferin (P,0.05,
Figure 1B). CPT-1 and ACC are the rate-limiting enzymes for
FFA b-oxidation and synthesis, respectively, in liver [22,23].
Mangiferin increased significantly the expression of CPT-1
(P,0.05, Figure 1C) and the level of ACC phosphorylation
(P,0.05, Figure 1D) which has been shown to reduce the activity
of the enzyme in a dose-dependent manner. Additionally, b-
hydroxybutyrate, a main intermediate metabolite of FFA
oxidation in liver [24], was increased significantly by mangiferin
in both plasma and liver of hyperlipidemic rats, which indicating
that FFA oxidation might be increased. DGAT2 is a key enzyme
that catalyzes the final step and rate-limiting reaction in TG
synthesis [25]. Mangiferin decreased DGAT2 expression signif-
icantly (P,0.05, Figure 1E) in liver of hyperlipidemic rats. These
results indicate collectively that mangiferin promotes the FFA
uptake and oxidation, and inhibits FFA and TG synthesis by
regulating the key enzymes expression in liver of hyperlipidemic
rats.
Mangiferin increased FFA uptake, decreased intracellular
FFA and TG accumulations in HepG2 cells
HepG2 cells were treated with OA (0.2 mmol/L) in order to
simulate the condition of high level of plasma FFA in animal
experiment. Mangiferin significantly decreased the OA con-
centration of cell culture medium in a dose-dependent manner,
and fenofibrate (positive control) at 100 mmol/L also signifi-
cantly decreased the OA concentrations (P,0.01, Figure 2A).
OA uptake by HepG2 cells was calculated by the concentration
of OA remaining in the medium after treatment. Compared
Table 1. Effect of mangiferin on fasting metabolic variables at 6 weeks in hyperlipemic rats.
Measurement Control Hyperlipidemia
Hyperlipidemia
+fenofibrate
(100 mg/kg BW)
Hyperlipidemia
+mangiferin
(50 mg/kg BW)
Hyperlipidemia
+mangiferin
(100 mg/kg BW)
Hyperlipidemia
+mangiferin
(150 mg/kg BW)
Body weight (g) 340.3624.9 378.5632.6
## 368.1634.7 371.2628.3 369.7635.1 361.4636.7
Food intake (g/day) 26.5662.17 33.2563.98
## 31.9763.01 32.2362.75 34.0262.70 32.1362.64
Liver weight (g) 8.4361.21 8.9761.33 8.7961.25 8.8861.24 8.8061.12 8.7161.08
Abdominal fat (g) 10.2361.28 15.1561.42
## 11.1661.27
** 14.4361.39 13.7961.41
* 12.8161.34
*
Epididymal fat (g) 8.7861.03 10.2361.24
# 8.9860.98
* 10.0261.15 9.4661.02 9.0461.12
*
Plasma TC (mmol/L) 3.7060.47 4.2660.61
# 3.8760.32
* 4.1560.47 4.0260.39 4.0860.37
Plasma TG (mmol/L) 0.8960.12 1.4660.18
## 0.9660.19
** 1.3760.22 1.2460.16
** 1.0560.10
**
Plasma FFA (mg/dl) 484.3637.5 587.6641.4
## 501.8636.2
** 541.6630.8
* 527.8633.9
** 493.5638.1
**
Plasma b-hydroxybutyrate
(mmol/L)
93.268.47 64.866.91
## 87.569.17
** 70.367.10 83.569.13
** 90.6610.01
**
Liver TC (mmol/g of liver) 5.8060.34 7.1860.37
## 6.5160.32* 7.0260.30 6.9860.38 6.8760.36
Liver TG (mmol/g of liver) 4.0660.22 5.1360.32
## 4.4360.37** 4.8960.33 4.4260.30
** 4.1260.39
**
Liver FFA (mmol/g of liver) 84.8614.4 153.5627.7
## 104.6622.4** 139.1621.9 118.6621.3
** 97.6623.8
**
Liver b-hydroxybutyrate
(mmol/g of liver)
7.2360.71 4.2360.57
## 6.8760.83
** 4.8860.50
* 5.8760.61
** 6.4360.78
**
Data are means 6 SD (n=10),
#P,0.05
##P,0.01 indicate statistically significant differences when compared with control group.
*P,0.05 and
**P,0.01 indicate statistically significant differences when compared with hyperlipidemia group.
doi:10.1371/journal.pone.0030782.t001
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100 mmol/L increased the OA uptake by 22.4%, 24.2% and
32.4% respectively. In addition, mangiferin at 50, 100 mmol/L
and fenofibrate significantly decreased the content of intracel-
lular OA (P,0.05, Figure 2B) and TG (P,0.05, Figure 2C) in
HepG2 cells. Further, the actual numbers used to generate the
relative results of Figure 2 are listed in supplementary Table S2.
These results indicate that mangiferin could decrease the level
o fF F Ai nm e d i u ma n di n h i b i tT Ga c c u m u l a t i o ni nh e p a t i c
cells.
Mangiferin regulated the key enzymes of FFA
metabolism and TG synthesis in HepG2 cells
To further confirm the mechanism of mangiferin on improving
FFA metabolism and inhibiting TG synthesis in vitro,w e
determined the protein levels of AMPK, CD36, CPT1, ACC
and DGAT2 in HepG2 cells by mangiferin supplementation.
Mangiferin significantly increased the phosphorylation levels of
AMPK and ACC (P,0.05, Figure 3A, 3D), the protein levels of
CD36 and CPT1 (P,0.05, Figure 3B, 3C), but decreased
significantly the protein level of DGAT2 (P,0.05, Figure 3E).
Figure 1. Effects of mangiferin on the proteins expression of FFA metabolism including AMPK, CD36, CPT1, ACC and DGAT2 in liver
of hyperlipidemic rats. Wistar rats were divided randomly into five groups (n=10 per group): control group (fed an AIN-93G diet); hyperlipidemia
group (fed a high-fat diet); mangiferin-supplemented groups, fed the high-fat diet and different doses of mangiferin (50, 100, 150 mg/kg BW/d). The
experiment lasted for 6 weeks, and the liver was taken for western blot analysis. (A) AMPK phosphorylation level. (B) CD36 expression on cell
membrane. (C) CPT1 expression in mitochondrion. (D) ACC level and activity. (E) DGAT2 expression. * P,0.05 compared with hyperlipidemic group.
doi:10.1371/journal.pone.0030782.g001
Figure 2. Effects of mangiferin on OA in medium, intracellular OA and intracellular TG in HepG2 cells. HepG2 cells were incubated with
0.2 mmol/L OA only or with different concentrations of mangiferin (12.5, 25, 50, 100 mmol/L) or fenofibrate (100 mmol/L) simultaneously for 24 h. The
concentrations of OA in medium (A) and intracellular OA (B) after the incubation were determined by GC-MS. The intracellular TG (C) mass was
quantified by the enzymatic methods using a TG test kit. Data are presented as means 6 SD (n=3).
# P,0.05 and
## P,0.01 compared with the
normal control.
* P,0.05 and
** P,0.01 compared with only OA stimulation group.
doi:10.1371/journal.pone.0030782.g002
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and oxidation, inhibit FFA and TG synthesis by regulating the key
enzymes expression in HepG2 cells.
AMPK was involved in the effect of mangiferin on FFA
metabolism and TG synthesis in HepG2 cells
Compound C, an AMPK inhibitor, abolished almost completely
the activation of AMPKa by mangiferin. The effects of mangiferin
on OA uptake, intracellular OA and TG (Figure 4A) contents, as
well as the expression of AMPK downstream proteins, including
CD36, CPT1, P-ACC and DGAT2 were also suppressed signifi-
cantly after compound C treatment (P,0.05, Figure 4B). These
results strongly suggest that mangiferin exerts its effect on lowering
plasma FFA level, promoting FFA uptake and oxidation, inhibiting
FFA and TG synthesis via the AMPK signaling pathway in liver.
AMPK was phosphorylated and activated by AMP/ATP
but not LKB1 in mangiferin signaling in HepG2 cells
To investigate how mangiferin activates AMPK, we determined
the effect of mangiferin on upstream of AMPK, including the ratio
of AMP to ATP and LKB1 activity and protein expression [26].
Mangiferin increased the ratio of AMP to ATP in a dose-
dependent manner in HepG2 cells (P,0.05, Figure 5A). However,
neither the content of LKB1 nor the ratio of p-LKB1/LKB1 was
altered significantly by mangiferin (Figure 5B). These results
indicate that mangiferin activates AMPK by increasing the ratio of
AMP to ATP instead of LKB1 in present study.
Discussion
There is considerable public and scientific interest in the various
beneficial biological activities of mangiferin, including antioxidant,
anti-inflammatory and anti-diabetic effects [9,10]. However, there
are few studies about the effect of mangiferin on dyslipidemia.
Miura and Huang et al [11,27] reported only that mangiferin may
decrease the levels of blood TC and TG [11,12], and that the
mechanism is not yet clear. FFA is a major component of blood
lipids and plays a key role in regulating blood lipid levels,
especially in triglycerides metabolism [28]. In addition, elevated
plasma FFA is a risk factor for metabolic syndrome, which can
lead to hyperlipidemia, fatty liver and insulin resistance [2,29].
However, there is no report about the effect of mangiferin on FFA
levels and FFA metabolism.
In vivo, we used a high-fat diet to induce hyperlipidemia model
in rats. The rats in hyperlipidemia groups had higher body weight,
plasma TC, TG and FFA levels and liver TC, TG and FFA levels
compared to rats in normal control group. These results indicated
that the hyperlipidemic rats model with triglycerides and
cholesterol accumulation in the liver was induced successfully by
the high-fat diet. In order to study further the mechanism
improving FFA metabolism in vitro, HepG2 cells were treated with
OA (0.2 mmol/L) to simulate the condition of high plasma levels
of FFA in animal experiment. As a result, 0.2 mmol/L OA
increased significantly the intracellular TG content in liver cells, a
condition that is observed often when plasma FFA is elevated in
human and animal studies. Fenofibrate, a hypotriglyceride drug as
positive control agent, can reduce plasma FFA and hepatic TG
[30]. In our study, fenofibrate significantly increased FFA uptake,
and decreased intracellular FFA and TG in HepG2 cells,
indicating that using OA-treated HepG2 cells to study the effect
of mangiferin on FFA metabolism is feasible.
We have confirmed that the doses of mangiferin used in this
study are safe based on the toxicity experiment of 30-day feeding
test and MTT assay both in vivo and in vitro. Our study showed for
Figure 3. HepG2 cells were incubated with 0.2 mmol/L OA only or with different concentrations of mangiferin (12.5, 25, 50,
100 mmol/L) simultaneously for 24 h. Proteins were isolated from the cell lysates and analyzed by western blot analysis for AMPK (A), CD36 (B),
CPT1 (C), ACC (D) and DGAT (E) expressions. The experiments were repeated 3 times. Data are presented as means 6 SD (n=3).
* P,0.05 compared
with only OA stimulation group.
doi:10.1371/journal.pone.0030782.g003
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levels in hyperlipidemic rats and FFA levels in culture medium of
HepG2 cells. It is well known that plasma FFA is mainly
transported into the liver at rest. CD36 is the rate-limiting enzyme
in high-affinity peripheral FFA uptake in the liver [21,31]. We
have found that CD36 is involved in the increased FFA uptake
supplemented with mangiferin in liver of hyperlipidemic rats and
in OA induced HepG2 cells, a conclusion that is supported by the
increase of CD36 protein expression. Mangiferin increased FFA
uptake, decreased the liver FFA levels in hyperlipidemic rats and
in HepG2 cells, which indicates an increased FFA utilization in
liver. In the liver, FFA is converted intracellularly into fatty-acyl-
CoA to produce energy in the form of long-chain fatty-acyl-CoAs
(LCACoAs) through b-oxidation or esterification into TG [8]. b-
hydroxybutyrate (ketone body) is the main alternative energy
substrate to glucose, and is generated by hepatic fatty acid
oxidation in liver when plasma glucose and insulin are low [32].
Mangiferin increased the levels of b-hydroxybutyrate both in
blood and liver in our study, indicating that mangiferin could
increase FFA oxidation. In addition, CPT-1 is the rate-limiting
enzyme for LCACoAs transport from the cytoplasm into the
mitochondria in FFA b-oxidation. The activity of CPT-1 is
inhibited by malonyl-CoA. The inhibition of ACC activity leads to
a reduced malonyl-CoA production, resulting in the suppression of
FFA synthesis and, reciprocally, the enhancement of FFA b-
oxidation [33]. In our experiment, mangiferin increased signifi-
cantly CPT-1 protein expression and inhibited ACC activity in
liver of hyperlipidemic rats and in OA induced HepG2 cells,
indicating that mangiferin could significantly increase fatty acid b-
oxidation. DGAT2 is a rate-limiting enzyme that catalyzes the
final step in TG synthesis by facilitating the linkage of
diacylglycerol with a long chain fatty acyl-CoA [25]. Mangiferin
decreased the expression of DGAT2 protein in the liver of
hyperlipidemic rats and in OA induced HepG2 cells, indicating
that mangiferin could reduce the biosynthesis of intracellular TG
from fatty acid. Taken together, these observations suggest that
Figure 4. Effects of compound C on mangiferin induced FFA uptake, intracellular FFA, TG and FFA metabolism proteins expression
in HepG2 cells. HepG2 cells were pretreated 1 h with compound C, an AMPK inhibitor, and then treated with 100 mmol/L mangiferin and 0.2 mmol/
L OA for 24 h. OA in medium (To assess the uptake of OA) (A), intracellular OA (A), intracellular TG (A) and proteins expression of FFA metabolism
including AMPK (B), ACC (B), CD36 (B), CPT1 (B) and DGAT2 (B) were determined by western blot method. The experiments were repeated 3 times.
Data are presented as means 6 SD (n=3).
* P,0.05 and
** P,0.01 compared with only OA stimulation group.
doi:10.1371/journal.pone.0030782.g004
Figure 5. Effects of mangiferin on the ratio of AMP to ATP and LKB1 protein expression in HepG2 cells. HepG2 cells were incubated to
0.2 mmol/L oleic acid only or with different concentrations of mangiferin (12.5, 25, 50, 100 mmol/L) simultaneously for 24 h. The ratio of AMP to ATP
was detected by HPLC (A). The LKB1 protein expression was carried out by western blot analysis (B). The experiments were repeated 3 times. Data are
presented as means 6 SD (n=3).
* P,0.05 compared with only OA stimulation group.
doi:10.1371/journal.pone.0030782.g005
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in liver.
AMPK, an upstream regulator of CD36, CPT1, ACC and
DGAT2, is a critical enzyme involved in FFA metabolism [26]. It
plays an important role in lipid metabolism and FFA oxidation in
the liver [20]. Results from our study verified that the AMPK
pathway mediates the effect of mangiferin on FFA metabolism
toward an enhancement of fatty acid b-oxidation and inhibition of
TG synthesis in liver of hyperlipidemic rats and in HepG2 cells.
High ratio of AMP to ATP, and LKB1 as an upstream kinase, can
activate AMPK. In this study, mangiferin increases the ratio of
AMP to ATP in a dose-dependent manner, but has no effect on
LKB1 phosphorylation, indicating that the effect of mangiferin on
AMPK is accomplished through its effect on the ratio of AMP to
ATP. However, the mechanism of how mangiferin causes an
increase in the ratio of AMP to ATP needs to be studied further.
In conclusion, we investigated systematically the effect of
mangiferin on FFA levels and FFA metabolism, and its possible
mechanism for the first time. Mangiferin decreases the levels of
FFA in both plasma and liver tissue in hyperlipidemic rats,
promotes FFA catabolism by regulating the key enzymes of FFA
uptake and utilization and inhibiting intracellular TG synthesis in
liver. The effect of mangiferin on decreasing plasma FFA levels
and increasing FFA catabolism is possibly exerted through the
AMPK pathway by enhancing the ratio of AMP to ATP.
Therefore, mangiferin results in beneficial effects on FFA
metabolism, which may improve metabolic syndrome.
Materials and Methods
Animals
All rats were purchased from Shanghai SLAC Laboratory.
Animals were housed in cages individually in an environmentally
controlled room at 2162.0uC and 5065% humidity. Animals
were subject to a 12:12 h light:dark cycle and had access to food
and water ad libitum. After an acclimatization period of one week,
the animals were used in the following experiments.
Experiment I. Forty male rats and forty female rats
(100620 g) were divided into 4 groups respectively, 10 rats in
each group, treated with different concentrations of mangiferin (0,
100, 200, 400 mg/kg BW) by oral gavage for 30 days. The blood
chemistry results, hematologic measures, and liver enzyme values
were determined by using SYSMEX-SF-3000 Automatic
Hematology Analyzer (Sysmex corporation, Kobe, Japan).
Experiment II. Sixty male rats (220620 g) were divided
randomly into six groups (n=10 in each group): control group, fed
an AIN-93G diet; hyperlipidemia group, fed a high-fat diet (48.1%
of energy derived from fat, 34.2% from carbohydrates, and 17.7%
from protein); positive drug group, fed a high-fat diet and
fenofibrate at dose of 100 mg/kg BW/d; mangiferin-
supplemented groups, fed the high-fat diet and different doses of
mangiferin (50, 100, 150 mg/kg BW/d). Mangiferin (.90%,
HPLC; Tianjin zhongxin pharmaceutical Group Co Ltd, Tianjin,
China) and fenofibrate was given by oral gavage in 1%
carboxymethyl cellulose buffer solution. Rats in the control and
hyperlipidemia groups were given 1% carboxymethyl cellulose
buffer only. After 6 weeks of mangiferin supplementation, all the
animals were fasted for 12 h until sacrifice. Rats were anesthetized
by pentobarbital sodium and blood samples were taken from
abdominal aorta into EDTA-tubes. Abdominal and epididymal fat
pads were removed and weighted separately. Liver was collected
and stored at 280uC for analysis. The experimental protocols
were approved by the Institutional Animal Care and Use
Committee of Harbin Medical University, and conducted in
compliance with the animal-use guidelines (SYXK (Hei) 2006-
010).
Reagents
Dulbecco’s Modified Eagle Medium (DMEM) was purchased
from GIBCO (Grand Island, NY). Fetal bovine serum (FBS) was
purchased from Sijiqing Co (Hangzhou, China). Mangiferin for
cell experiment, oleic acid (OA), fenofibrate and compound C
were obtained from Sigma-Aldrich (St. Louis, MO). Mangiferin
(90%, HPLC) for animal experiment were obtained from
Zhongxin Innova Laboratories (Tianjin, China). Mangiferin,
fenofibrate and compound C were dissolved in dimethyl sulfoxide
(DMSO) and diluted with culture medium. Antibodies against
AMP-activated protein kinase a (AMPKa), phosphor-AMPKa (p-
AMPKa), acetyl CoA carboxylase (ACC) and phosphor-ACC (p-
ACC) were purchased from Cell Signaling (Beverly, MA).
Antibody against fatty acid translocase (CD36) was purchased
from Cayman Chemical (Ann Arbor, MI). Antibodies against
LKB1, phosphor-LKB1, carnitine palmitoyltransferase 1 (CPT-1),
acyl-CoA: diacylglycerol acyltransferase-2 (DGAT2), GAPDH and
b-actin were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA).
Cell culture and treatment
The HepG2 cell line was obtained from the Chinese Academy
of Science (Shanghai, China). The cells were maintained in
DMEM containing 10% (v/v) FBS and 1% antibiotic/antimycotic
at 37uC in an atmosphere containing 95% air and 5% CO2. The
cytotoxicity of mangiferin was determined by the 3-(4, 5-
Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT)
assay. When 70–80% confluence was reached, the cells were
treated with different concentrations of mangiferin (0, 12.5, 25, 50,
100 mmol/L) or 100 mmol/L fenofibrate (positive control) in
serum-free medium with 1% FFA-free bovine serum albumin
(BSA) in the presence of OA (0.2 mmol/L) for 24 h. In parallel,
HepG2 cells treated with an equivalent volume of DMSO (0.1%)
without OA were used as the normal control. HepG2 cells were
treated with OA (0.2 mmol/L) in order to simulate the condition
of high level of plasma FFA in liver cells. Compound C (25 mmol/
L) was added to HepG2 cells 1 h before treatment with mangiferin
to verify the AMPK signal pathway.
Determination of total cholesterol (TC), TG, FFA and b-
hydroxybutyrate in plasma and liver tissue
A portion of liver was homogenized and the lipids were
extracted with Chloroform and methanol (1:2 v/v) 2 times as
described by Bligh et al [15], and the supernatant were collected
for the determination of TC, TG and FFA. TC and TG were
determined by enzymatic colorimetric methods with commercial
kits (Zhongsheng, Beijing, China), FFA was determined by GC-
MS(TRACE GC/PolarisQ MS, Thermo Finnigan, USA) as
described previously by our laboratory [16]. b-hydroxybutyrate
concentrations in blood and liver were spectrophotometrically
assayed by commercial test kits (Co-health Ltd, Beijing, China)
[17].
Determinations of intracellular TG, intracellular OA and
OA uptake in medium in HepG2 cells
HepG2 cells were incubated with 0.2 mmol/L OA alone, or
with different concentrations of mangiferin (12.5, 25, 50,
100 mmol/L) or 100 mmol/L fenofibrate simultaneously in
serum-free medium with 1% FFA-free BSA for 24 h. The cellular
lipid was extracted using a previously described method [18]. Cell
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TG mass was quantified spectrophotometrically at 490 nm using a
TG test kit (Zhongsheng, Beijing, China). The experiments were
repeated three times.
The concentration of OA remaining in the medium after
treatment was determined to assess the uptake of OA by HepG2
cells. OA was measured by GC-MS (TRACE GC/PolarisQ MS,
Thermo Finnigan, USA). Aliquots (1 mL) of cell culture medium,
or 200 mL of cell lysates in each group were spiked with an internal
standard (IS) working solution (200 mL heptadecanoic acid C17:0,
200 mg/mL), and the following method of sample pretreatment
and GC-MS conditions was used, as described previously by our
laboratory [16].
Western blot analysis for the key proteins and enzymes
of FFA metabolism
The proteins CD36, CPT-1, ACC, DGAT2, AMPK and LKB1
were determined by western blot analysis. Proteins from the
cultured cells or liver tissues were extracted with a RIPA lysis
buffer (50 mmol/L Tris, pH 7.4, 150 mmol/L NaCl, 1% Triton
X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mg/mL leupeptin,
50 mmol/L sodium fluoride, 1 mmol/L sodium orthovanadate,
1 mmol/L phenylmethylsulfonyl fluoride). Protein concentrations
were determined by the Bradford method. Equal amounts of
protein were separated by SDS-PAGE, and electro-transferred
onto polyvinylidene difluoride (PVDF) membranes. The mem-
branes were blocked with 1% BSA and TBS-T (50 mmol/L Tris-
HCl, pH 7.5, 150 mmol/L NaCl, 0.1% Tween 20) for 0.5 h at
room temperature. The membranes were incubated overnight at
4uC with primary antibodies in TBS-T. The membranes were
washed three times with TBS-T (6 minutes each), and incubated
with appropriate secondary antibodies for 1 h at room tempera-
ture. The signal was amplified by color development using the
ProtoBlot II AP System with a stabilized substrate (Promega
Corporation, Madison, USA). Data were presented as the ratios of
target protein to b-actin. For each study, western blot analysis was
conducted three times and representative blots were shown.
Measurements of intracellular AMP and ATP in HepG2
cells
After the treatment as described above, cells were lysed in
300 m L media with 20 m L of 1 mol/L HClO4. HClO4 was
removed by mixed phase extraction employing tri-n-octylamine
and Freon 11 (11.75:13.25; v/v) [19]. Lysates were analzyed by
HPLC on a Waters C18 column, using a Waters 2695 Separations
Module and a 2487 Dual Absorbance Detector (Waters Corpo-
ration, USA). The HPLC system consisted of 0.1 mol/L
potassium phosphate buffer (contain 3 mmol/L tetrabutylammo-
nium hydrogen, pH=5.85) and methanol (88:12) as the mobile
phase, with the detection wavelength at 254 nm, and the flow rate
at 1 mL/min. Experiments were repeated three times.
Statistical analysis
All data were analyzed for statistical significance with SPSS 13.0
software. Data were presented as means 6 standard deviation.
Statistical analysis used one-way ANOVA. P,0.05 was considered
to be statistically significant.
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